WO2017135909A1 - Formulation of egg yolk oil, chitosan gel and egf for the treatment of burns - Google Patents

Formulation of egg yolk oil, chitosan gel and egf for the treatment of burns Download PDF

Info

Publication number
WO2017135909A1
WO2017135909A1 PCT/TR2016/050332 TR2016050332W WO2017135909A1 WO 2017135909 A1 WO2017135909 A1 WO 2017135909A1 TR 2016050332 W TR2016050332 W TR 2016050332W WO 2017135909 A1 WO2017135909 A1 WO 2017135909A1
Authority
WO
WIPO (PCT)
Prior art keywords
egg yolk
yolk oil
chitosan gel
production method
medicine formulation
Prior art date
Application number
PCT/TR2016/050332
Other languages
French (fr)
Inventor
Evrim YENILMEZ
Ebru BASARAN
Rana ARSLAN
Murat Sami BERKMAN
Umay Merve GÜVEN
Yasemin YAZAN
Original Assignee
Anadolu Universitesi Rektorlugu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadolu Universitesi Rektorlugu filed Critical Anadolu Universitesi Rektorlugu
Publication of WO2017135909A1 publication Critical patent/WO2017135909A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • This invention is related to a formulation involving egg yolk oil and chitosan which is used in topical treatment of the dermal burns and a production method.
  • Burn damage which is developed due to the fact that the organism topically faces with fire, vapour and hot objects is called "burn". Burn damage depends on protein denaturation and various depths and widths are observed depending on the contact time with the factor and the intensity. Burn is a type of injury, always including the skin and skin layers which damages the other organs time to time in the body.
  • Epidermal growth factor (EGF) is a growth factor having a significant role on cell growth, proliferation and differentiation. It shows the effect by connecting its own receptor EGFR. They are the proteins of which weight differs between 4000-60000 dalton and in small quantities that can affect the cellular activity thereof.
  • Various preparates are used in burn injury treatment in our country.
  • Purpose of the invention is to achieve a medicine formulation that purposes the rapid and effective treatment of the dermal burns.
  • Another purpose of the invention is to achieve a medicine formulation which is topically applied in gel structure.
  • Another purpose of the invention is to achieve a medicine formulation of which stability test is carried, involving egg yolk oil and chitosan.
  • ⁇ ekil 2 - Figure 2 is a graphic wherein the effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin ® ) availably used in the market on burn injury granulation tissue formation are compared.
  • ⁇ ekil 3 - Figure 3 is a graphic wherein the effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin ® ) availably used in the market on burn injury collagen fiber formation are compared.
  • ⁇ ekil 4 - Figure 4 is a graphic wherein the effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin ® ) availably used in the market on burn injury re-epithelialization change are compared.
  • ⁇ ekil 5 - Figure 5 is a graphic wherein the general histological effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin ® ) availably used in the market on burn injury recovery are compared.
  • ⁇ ekil 6 - Figure 6 is a graphic wherein the effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin ) availably used in the market on burn injury size change are compared.
  • the production method of the medicine formulation (100) which is the subject of the invention comprises the step processes;
  • EGF epidermal growth factor
  • Dermal medicine formulation which is the subject of the invention is developed particularly for the topical treatment of burns and basically comprises egg yolk oil, chitosan and epidermal growth factor.
  • a dermal medicine formulation 100
  • the egg yolk oil is procured (10)
  • the chitosan gel is prepared (102) to be mixed with.
  • egg yolks that are separated from the egg white of the boiled eggs with the intent of procuring the egg yolk oil (101) are burned in teflon cups on the high heat in fume hood.
  • the cinders formed during the burning process are filtered and degreased under pressure.
  • egg yolks that are separated from the egg white are burned in teflon cups on the high heat in fume hood.
  • egg yolk oil is procured and filtered (101).
  • EGF epidermal growth factor
  • pH value of the final mixture procured varies between 5-5,5 and the viscosity varies between 7500-8500 mPa.s.
  • Dermal medicine formulation which is procured with the method (100), the subject of the invention, is tested on albino Wistar rats as in vivo.
  • the animals are kept in different cages at 22°C room temperature on their own.
  • the experimental animals are separated into 6 groups and 16 rats are used in each group.
  • the animals are firstly anesthetized with xylazine (1 mg/kg) and ketamine (5 mg/kg) and then the hairs on the back area are shaved. After cleaning and sterilizing the shaved area with 70% alcohol and physiological saline solution, burn is ready to be effectuated.
  • a metal apparatus modified with 1,5 cm diameter, 1 mm thickness and 30 g weight is used. After the metal apparatus is heated up to 85°C (this heating value is procured by keeping the apparatus for 10 seconds at the high heat) and the temperature is detected via UV heat meter, an extra pressure is applied to the shaved area of the rats for 20 seconds. Burns are effectuated on the back of each rat. After the burns are effectuated, size measurements of the burns are made and the experimental animals are fed with standard feeds by keeping them in different sterile cages.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is related to a formulation involving egg yolk oil and chitosan which is used in topical treatment of the dermal burns and a production method that includes the following step processes; procuring egg yolk oil (101), preparing chitosan gel (102), preparing egg yolk oil and chitosan gel mixture (103) and adding epidermal growth factor (EGF) into the mixture and mixing (104).

Description

DESCRIPTION
FORMULATION OF EGG YOLK OIL, CHITOSAN GEL AND EGF FOR THE TREATMENT OF BURNS
Technical Field
This invention is related to a formulation involving egg yolk oil and chitosan which is used in topical treatment of the dermal burns and a production method.
Prior Art
Biological tissue damage which is developed due to the fact that the organism topically faces with fire, vapour and hot objects is called "burn". Burn damage depends on protein denaturation and various depths and widths are observed depending on the contact time with the factor and the intensity. Burn is a type of injury, always including the skin and skin layers which damages the other organs time to time in the body. Epidermal growth factor (EGF) is a growth factor having a significant role on cell growth, proliferation and differentiation. It shows the effect by connecting its own receptor EGFR. They are the proteins of which weight differs between 4000-60000 dalton and in small quantities that can affect the cellular activity thereof. Various preparates are used in burn injury treatment in our country. In addition, women in Anatolia use egg yolk oil which are procured in stagnant conditions on the burn injuries. It is scientifically studied that it contains egg yolk, cholestrol, phospholipids, vitamins, minerals and cephalin. Proteins are found as connected to lipids. Chitosan, which is the most common biopolymer to encounter in nature subsequent to cellulose, having reactive functional amino groups and resembling cellulose in terms of chemical structure that can be found in the external skeleton of the shellfish such as crab and shrimp, in the wings of the butterflies and the cell walls of the mushroom, is procured from chitin that is natural polysaccharide via deasetilation method. It is supported in the studies that chitosan has a wound healing effect.
A formulation purposes the dermal usage of egg yolk oil and chitosan together has not been developed yet. Brief Description of the Invention
Purpose of the invention is to achieve a medicine formulation that purposes the rapid and effective treatment of the dermal burns. Another purpose of the invention is to achieve a medicine formulation which is topically applied in gel structure.
Another purpose of the invention; is to achieve a medicine formulation of which stability test is carried, involving egg yolk oil and chitosan.
Detailed Description of the Invention
The figures related to "a dermal medicine formulation and production method" which is developed in order to achieve the purpose of the invention are attached below; §ekil 1 - Figure 1 is a flow chart belonging to the method which is the subject of the invention.
§ekil 2 - Figure 2 is a graphic wherein the effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin®) availably used in the market on burn injury granulation tissue formation are compared.
§ekil 3 - Figure 3 is a graphic wherein the effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin®) availably used in the market on burn injury collagen fiber formation are compared.
§ekil 4 - Figure 4 is a graphic wherein the effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin®) availably used in the market on burn injury re-epithelialization change are compared.
§ekil 5 - Figure 5 is a graphic wherein the general histological effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin®) availably used in the market on burn injury recovery are compared.
§ekil 6 - Figure 6 is a graphic wherein the effects of the various combinations of the materials used in the method which is the subject of the invention, control sample and a dermal medicine formulation (Silverdin ) availably used in the market on burn injury size change are compared.
The production method of the medicine formulation (100) which is the subject of the invention comprises the step processes;
- procuring the egg yolk oil (101),
- preparing chitosan gel (102),
- preparing egg yolk oil and chitosan gel mixture (103),
- adding epidermal growth factor (EGF) into the mixture and mixing (104).
Dermal medicine formulation which is the subject of the invention is developed particularly for the topical treatment of burns and basically comprises egg yolk oil, chitosan and epidermal growth factor. In the production method of a dermal medicine formulation (100), while the egg yolk oil is procured (10), at the same time, the chitosan gel is prepared (102) to be mixed with.
In an implementation of the invention, egg yolks that are separated from the egg white of the boiled eggs with the intent of procuring the egg yolk oil (101) are burned in teflon cups on the high heat in fume hood. The cinders formed during the burning process are filtered and degreased under pressure.
In a preferable implementation of the invention, when the eggs are raw, egg yolks that are separated from the egg white are burned in teflon cups on the high heat in fume hood. By pressurizing the cinders formed during the burning process, egg yolk oil is procured and filtered (101).
The oil procured, with the intent of stability control, by being placed into the stability cabinets with 60% relative humidity and various temperatures (4°C, 25°C, 40°C) is periodically (15 days later, 1 month later, 2 months later, 3 months later etc.) controlled in terms of pH, viscosity and droplet size.
On the other hand, in order to get rid of the air bubbles by mixing the 0,5% acetic acid solution with chitosan and keeping the mixture waiting at least for 1 day, 2% chitosan gel is prepared (102). Mixing process is carried out for 4 hours for 10-gram mixture in magnetic stirrer.
For 1000 μΙ_, of the egg yolk oil that is procured, 10-gram chitosan gel is used and a mixture is prepared (103) by preferably mixing these two materials for 1 hour in magnetic stirrer. pH and viscosity-measurement of the mixture prepared are performed. pH value varies between 5-5,5 and viscosity varies between 8200-8400 mPa.s.
10 μg/ml epidermal growth factor (EGF) is added into the egg yolk oil and chitosan gel mixture prepared and the mixing process is preferably applied for 1 hour in magnetic stirrer (104).
After pH and viscosity measurements of the mixture involving egg yolk oil, chitosan and EGF are made, stability tests are carried out and therefore, the dermal medicine formulation which is the subject of the invention is procured. pH value of the final mixture procured varies between 5-5,5 and the viscosity varies between 7500-8500 mPa.s.
Dermal medicine formulation which is procured with the method (100), the subject of the invention, is tested on albino Wistar rats as in vivo.
Within the scope of the experiment, the animals are kept in different cages at 22°C room temperature on their own. The experimental animals are separated into 6 groups and 16 rats are used in each group. In the study, it is planned to use 96 rats, yet, during some experiments that are carried out in winter months, some injured rats are dead due to hypothermia because of the bad weather conditions. Due to this reason, new rats are added in return for the dead rats and the total number of the experimental animals used is more than the expectation.
The animals are firstly anesthetized with xylazine (1 mg/kg) and ketamine (5 mg/kg) and then the hairs on the back area are shaved. After cleaning and sterilizing the shaved area with 70% alcohol and physiological saline solution, burn is ready to be effectuated.
In order to effectuate burn, a metal apparatus modified with 1,5 cm diameter, 1 mm thickness and 30 g weight is used. After the metal apparatus is heated up to 85°C (this heating value is procured by keeping the apparatus for 10 seconds at the high heat) and the temperature is detected via UV heat meter, an extra pressure is applied to the shaved area of the rats for 20 seconds. Burns are effectuated on the back of each rat. After the burns are effectuated, size measurements of the burns are made and the experimental animals are fed with standard feeds by keeping them in different sterile cages.
By applying the various formulations in which the dermal medicine formulation that is the subject of the invention also exists on different rats with the intent of treatment, the effects are observed. The tissue samples taken from the rats in 7th, 14th and 21st days are histologically evaluated. Paraffin-embedded samples are sectioned for this purpose and then by hemotoxilen-eosine staining, these samples are evaluated in terms of formation of granulation tissue, formation of collagen fiber, re- epithelialization and general recovery under light microscope. Besides, during the treatment of these injuries, size changes are observed. Said observations and evaluations are indicated with Figure 2, Figure 3, Figure 4, Figure 5 and Figure 6.
Consequently, according to in vivo tests made with rats it is observed that the egg yolk oil and chitosan gel involving EGF formulation which is procured with the method (100), the subject of the invention, is the most effective formulation for the burn treatments and it constitutes a preferable alternative comparing to the other preparates (such as Silverdin®) in the market.

Claims

1. Production method of a dermal medicine formulation (100) which is developed in order to be used in topical treatments of burns is characterized by the step processes below;
- procuring the egg yolk oil (101),
- preparing chitosan gel (102),
- preparing egg yolk oil and chitosan gel mixture (103),
adding epidermal growth factor (EGF) into the mixture and mixing (104).
According to Claim 1, production method of a dermal medicine formulation (100) is characterized by the step process wherein egg yolk oil is procured (101) by burning the egg yolk that are separated from egg white of the boiled eggs in teflon cups at the high heat in fume hood and by filtering the cinders formed during the burning process degreasing under pressure.
According to Claim 1, production method of a dermal medicine formulation (100) is characterized by the step process wherein egg yolk oil is procured (101) by burning the egg yolk that are separated from egg white of the raw eggs in teflon cups at the high heat in fume hood and by filtering the cinders formed during the burning process degreasing under pressure.
According to Claim 1, production method of a dermal medicine formulation (100) is characterized by the step process wherein 2% chitosan gel (102) is prepared by mixing the 0,
5% acetic acid solution with chitosan and keeping the mixture waiting at least 1 day in order to get rid of the air bubbles.
According to Claim 4, production method of a dermal medicine formulation (100) is characterized by the step process wherein chitosan gel (102) is prepared by the applying the mixing process for 4 hours in the magnetic stirrer for 10-gram chitosan gel.
6. According to Claim 1, production method of a dermal medicine formulation (100) is characterized by the step process wherein egg yolk oil and chitosan gel mixture is prepared (103) by using 10-gram chitosan gel for 1000 μΙ_, egg yolk oil.
7. According to Claim 6, production method of a dermal medicine formulation (100) is characterized by the step process wherein egg yolk oil and chitosan gel mixture is prepared (103) by mixing the egg yolk oil and chitosan gel in magnetic stirrer for 1 hour.
8. According to Claim 1, production method of a dermal medicine formulation (100) is characterized by the step process wherein 10 μg/ml epidermal growth factor (EGF) is added into the egg yolk oil and chitosan gel mixture and mixing (104).
9. According to Claim 8, production method of a dermal medicine formulation (100) is characterized by the step process wherein epidermal growth factor (EGF) is added into the mixture and mixing in magnetic stirrer for 1 hour (104).
10. A dermal medicine formulation to be used in topical treatment of the burns of which pH value is between 5 and 5,5 and the viscosity value is between 7500-8500 mPa.s is procured with a method (100) according to any claim described above.
PCT/TR2016/050332 2016-02-05 2016-09-05 Formulation of egg yolk oil, chitosan gel and egf for the treatment of burns WO2017135909A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2016/01571 2016-02-05
TR201601571 2016-02-05

Publications (1)

Publication Number Publication Date
WO2017135909A1 true WO2017135909A1 (en) 2017-08-10

Family

ID=57256399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2016/050332 WO2017135909A1 (en) 2016-02-05 2016-09-05 Formulation of egg yolk oil, chitosan gel and egf for the treatment of burns

Country Status (1)

Country Link
WO (1) WO2017135909A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219544A (en) * 1979-02-26 1980-08-26 Burg Carol J Method for treating burns using an egg yolk oil
WO2014166483A1 (en) * 2013-04-12 2014-10-16 Nawrocki Werner Ch Method for producing and an egg oil composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219544A (en) * 1979-02-26 1980-08-26 Burg Carol J Method for treating burns using an egg yolk oil
WO2014166483A1 (en) * 2013-04-12 2014-10-16 Nawrocki Werner Ch Method for producing and an egg oil composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CEREN ALEMDAROGLU ET AL: "An investigation on burn wound healing in rats with chitosan gel formulation containing epidermal growth factor", BURNS, vol. 32, no. 3, 1 May 2006 (2006-05-01), pages 319 - 327, XP055048264, ISSN: 0305-4179, DOI: 10.1016/j.burns.2005.10.015 *
DEGIM ZELIHAGÜL ET AL: "Evaluation of chitosan gel containing liposome-loaded epidermal growth factor on burn wound healing.", INTERNATIONAL WOUND JOURNAL AUG 2011, vol. 8, no. 4, August 2011 (2011-08-01), pages 343 - 354, XP002765135, ISSN: 1742-481X *
E YENILMEZ ET AL: "Chitosan gel formulations containing egg yolk oil and epidermal growth factor for dermal burn treatment", DIE PHARMAZIE, 1 February 2015 (2015-02-01), Germany, pages 67 - 734126, XP055328107, Retrieved from the Internet <URL:http://docserver.ingentaconnect.com/deliver/connect/govi/00317144/v70n2/s1.pdf?expires=1481539528&id=89431318&titleid=75007325&accname=European+Patent+Office&checksum=5689975859329224B2A09B5968E5324F> [retrieved on 20161212], DOI: 10.1691/ph.2015.4126 *

Similar Documents

Publication Publication Date Title
CN102985091B (en) Use antimicrobial peptide chelate compound treatment dermatosis and abnormal compositions and method
CN105456050A (en) Freeze-dried powder, essence and skincare set for repairing acne marks and scars
US20220280680A1 (en) Coated silk films, methods for the production thereof and uses thereof
Yenilmez et al. Chitosan gel formulations containing egg yolk oil and epidermal growth factor for dermal burn treatment
CN104561206A (en) Collagen peptide easy to absorb
Vasconcelos et al. A phytomodulatory hydrogel with enhanced healing effects
DE1949195A1 (en) Process for the production of deproteinized blue extracts with medicinal properties
CN104840428A (en) Hyaluronic acid-chitosan microsphere carrying epidermal growth factor and preparation method and application of hyaluronic acid-chitosan microsphere
CN110947088A (en) Eye-protecting combined patch and preparation method thereof
WO2017135909A1 (en) Formulation of egg yolk oil, chitosan gel and egf for the treatment of burns
RU2646804C1 (en) Ophthalmic agent for regeneration of cornea of the eye
CN105998178A (en) Timolol external preparation for treating hemangioma
CN104707164B (en) Composite chitosan hydrogel dressing as well as preparation method and applications thereof
RU2560845C1 (en) Method for producing low-molecular activated embryonic complex (nika-em)
RU2350342C1 (en) Method of producing gel based on water extraction from unossified antlers
RU2669933C2 (en) Peptide medication from collagen for regeneration of skin tissue, method for its production and application
RU2481115C1 (en) Cellgel wound healing product, method for preparing it and method for healing of wounds of various aethiologies by prepared product
CN102908368A (en) Preparation method of virus lyophilized preparation
AT392003B (en) METHOD FOR PRODUCING A PARTICULARLY FOR Wounds Healing Or For Treatment In Geriatrics, Active Ingredients From Mammalian Blood By PAPAINE HYDROLYSIS AND A PREPARATION CONTAINING SUCH AN ACTIVE SUBSTANCE
CN115569110B (en) Recombinant type III collagen hydrogel composition, preparation method and application
Shokri et al. Effect of hydrophilic solvents on enhancing transdermal delivery of albumin
CN117281767B (en) Recombinant type III collagen hydrogel composition, preparation method and application thereof in medical skin and gynecological repair gel and mask
CN109078223A (en) Bionical wound repairing membrane and preparation method thereof
CN106177920A (en) Adipose tissue preparation for promoting wound healing and preparation method thereof
Simion et al. Multifunctional bioproducts obtained by innovative technologies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16794089

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16794089

Country of ref document: EP

Kind code of ref document: A1